INSTINCT BIO TECHNICAL CO HOLDINGS INC.
No enriched coverage for $BIOT in the last 7 days.
No SEC Form 4 filings for $BIOT in the last 30 days.
See all $BIOT insider activity →INSTINCT BIO TECHNICAL CO HOLDINGS INC. (BIOT) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Instinct Bio Returns to Profit and Grows Revenue Nearly 10% in Yen Terms in First Half of Fiscal 2026 TOKYO, October 16, 2026 -- Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) ("BIOT" or the "Company"), a Japan-based developer, manufacturer and seller of
Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) reported a 4.7% revenue increase to USD 1.14 million in 1H FY2026, with a 9.8% rise in yen terms. The company returned to profit, posting USD 90,251 in profit after tax, compared to a loss in the prior year. Gross margin decreased to 72.6% from 79.7%, while administrative expenses fell 30.1%. The company's largest customer's share of revenue dropped to 34.8% from 51.7%.
Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) was appointed as CelSiege Biosciences' authorized representative for IN01, a clinical-stage cancer immunotherapy, in Japan and China. BIOT will facilitate discussions on potential partnerships and investments for IN01, which targets lung cancer and other indications. The global NSCLC therapeutics market is estimated at $38.49 billion in 2025, according to Fortune Business Insights.
Recent BIOT coverage spans financial news, earnings and corporate actions.
First earnings disclosure for the newly listed company, indicating profit after a loss and a slight revenue increase.
The interim earnings beat expectations with profit after a prior loss, but cash is low and margins declined, suggesting modest upside with near‑term liquidity concerns.
The partnership could boost BIOT's pipeline visibility and potential licensing revenue, but the clinical-stage nature of IN01 limits immediate upside.
The clinic launch could boost future revenue and market visibility.
The MOA is a growth and commercialization framework, but it is not yet a definitive deal or regulatory-approved product launch.
AlphAI scores every news story that mentions BIOT with an AI model for sentiment and relevance, and aggregates insider trades from INSTINCT BIO TECHNICAL CO HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
INSTINCT BIO TECHNICAL CO HOLDINGS INC. (BIOT) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Instinct Bio Returns to Profit and Grows Revenue Nearly 10% in Yen Terms in First Half of Fiscal 2026 TOKYO, October 16, 2026 -- Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) ("BIOT" or the "Company"), a Japan-based developer, manufacturer and seller of
2 min readInstinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) reported a 4.7% revenue increase to USD 1.14 million in 1H FY2026, with a 9.8% rise in yen terms. The company returned to profit, posting USD 90,251 in profit after tax, compared to a loss in the prior year. Gross margin decreased to 72.6% from 79.7%, while administrative expenses fell 30.1%. The company's largest customer's share of revenue dropped to 34.8% from 51.7%.
2 min readInstinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) was appointed as CelSiege Biosciences' authorized representative for IN01, a clinical-stage cancer immunotherapy, in Japan and China. BIOT will facilitate discussions on potential partnerships and investments for IN01, which targets lung cancer and other indications. The global NSCLC therapeutics market is estimated at $38.49 billion in 2025, according to Fortune Business Insights.
2 min readInstinct Bio (NASDAQ:BIOT) secured a site in Jakarta for its GENREVER CLINIC, targeting a December 2026 opening. Subscription tiers are set at $400, $1,000, and $3,000 monthly. The company also announced product development plans with Invitrx Therapeutics and PT PARVA CANDELA, aiming for 2026 production starts.
1 min readInstinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) said its subsidiaries entered a Memorandum of Agreement with Invitrx Therapeutics, Inc. to expand GENREVER into the U.S. via a planned trademark license and U.S. GMP manufacturing, and to explore supplying exosomes and conditioned media for regenerative medicine initiatives in Indonesia. Definitive deals and regulatory approvals are pending.
3 min readInstinct Bio Technical Company Holdings Inc. (NASDAQ: BIOT) said it will launch GENRÊVER CLINIC in Indonesia, a subscription-model beauty clinic under its Japanese brand with a cancel-anytime membership structure. The company plans about $1 million to open five directly operated sites starting in Jakarta, Surabaya, Bandung, Medan and Bali, with Dr. Mario Damianus Daniel Hadinoto involved.
3 min readInstinct Bio (BIOT) shares fell 51.46% to $1.33 Tuesday and dropped another 20.30% in after-hours to $1.06. The Nasdaq-listed biotech completed a business combination with Relativity Acquisition Corp. It entered an indicative term sheet for an equity purchase facility to sell up to $150M of common stock over three years, priced near VWAP less a discount, to fund development and working capital.
3 min read